Summary
APLT Chart
Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now
Applied Therapeutics (APLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why
Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
February 18, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - APLT
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Applied Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Lu Chen Altitude Crest Partners Inc. | 259,700 | $1.77M | $1.77M | - | - |
| RJ Rebecca Judd Pathstone Holdings, LLC | 2.64M | $822,405.03 | $819,497.4 | -$2,907.63 | -0.35% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 84 | $2,746 | $2,745.96 | -$0.04 | - |
Applied Therapeutics Inc. (APLT) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Applied Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Les D. Funtleyder CEO | NASDAQ (NMS) Exchange | 03828A101 CUSIP |
| US Country | 35 Employees | - Last Dividend | - Last Split | 14 May 2019 IPO Date |
Overview
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative product candidates targeting molecular mechanisms with high unmet medical needs in the United States. The company concentrates on discovering treatments for diseases with limited or no current therapeutic options. Founded in 2016 and based in New York, New York, Applied Therapeutics aims to transform the lives of patients by harnessing the power of cutting-edge science to address challenges in the treatment of severe medical conditions.
Products and Services
- AT-007 (govorestat)
This lead product candidate has moved through phase 3 clinical trials and focuses on the treatment of galactosemia, a rare metabolic disorder. AT-007 has shown promise in healthy volunteers and has been studied in adult and pediatric populations. Beyond galactosemia, it also targets the enzyme sorbitol dehydrogenase and phosphomannomutase enzyme-CDG, showcasing its versatility in treating metabolic diseases.
- AT-001 (caficrestat)
In phase 3 of clinical development, AT-001 aims to address diabetic cardiomyopathy, a diabetes complication that affects the heart. The compound is also under study for the potential treatment of diabetic peripheral neuropathy, indicating Applied Therapeutics' commitment to combating the broader spectrum of diabetic complications with innovative therapies.
- AT-003
Currently in the preclinical study phase, AT-003 is being developed for the treatment of diabetic retinopathy, a condition that can lead to vision loss in people with diabetes. This demonstrates the company's focus on diabetic-related conditions and its dedication to preventing and treating complications arising from this global disease.
Additionally, Applied Therapeutics has entered into an exclusive license and supply agreement with Mercury Pharma Group Limited for the commercialization of drug products containing AT-007, marking an important step towards bringing their leading candidate to the market and fulfilling the company’s mission of addressing unmet medical needs.
